The drug makers in the Balkanpharma group, owned by Iceland’s Actavis, have worsened their financial performance in 2008, showed the reports filed with the commercial registrar.

Balkanpharma Troyan lowered its loss but sales slipped to BGN 28.75 million, the bulk of it generated by exports and only BGN 1.6 million from the domestic market.

Balkanpharma Razgrad ended the year with a 28% drop in profit as revenue slid 24%. The lion’s share of almost 92% of the receipts came from ten major customers and 46% of the revenue came from exports.

The group’s Dupnitsa unit saw its profit tumble to BGN 1.026 million from BGN 19.83 million in the previous year. Sales plunged by almost BGN 10 million, with exports fetching the bulk of the total. Last year the company finished the BGN 36.57 million revamp of its second tablet facility as part of a wide-ranging investment programme, which it claims have made it the largest solid pharmaceuticals producer in Southeastern Europe.